Building decision aids for prostate cancer screening in Australia
Prostate cancer remains the most commonly diagnosed cancer among Australian men, with more than 24,000 new cases recorded each year. Survival outcomes depend heavily on the stage at diagnosis, which has intensified national conversations about how men are counselled before undergoing a prostate-specific antigen (PSA) test.
Shared decision-making has emerged as the preferred framework for guiding men through the screening pathway. Rather than simply recommending a test, clinicians walk patients through the potential benefits, the false-positive risks, and the downstream consequences of investigation. A well-designed decision aid can anchor that conversation, allowing men to weigh their personal values against the available evidence.
Australia's geography adds another layer to the challenge. Men in outer-metropolitan Brisbane and across regional Queensland often have less access to urologists, longer waiting times for MRI, and limited access to multidisciplinary review. A decision aid that works in a Sydney tertiary centre may not resonate with a cattle farmer in Longreach.
This article explores how clinical researchers, consumer representatives, and policy groups are collaborating to build decision aids that are evidence-based, culturally safe, and practical for everyday use. It also highlights the role of translation networks in moving these resources from pilot studies into waiting rooms.
The Australian landscape for prostate cancer screening
National guidance from the Prostate Cancer Foundation of Australia and the Royal Australian College of GPs recommends that men aged 50 to 69 be offered PSA testing only after a balanced discussion of risks and benefits. Men with a family history are often advised to start conversations earlier.
Medicare-funded PSA tests are readily available, which makes the test easy to order but harder to contextualise. Many men still report receiving a script with little explanation. Closing that gap requires tools that prompt clinicians to pause, explain, and document preferences.
Public campaigns such as the regional "It's a Bloke Thing" roadshows in Queensland have shown that community-led education can shift attitudes. Decision aids complement these campaigns by providing a structured resource that patients can revisit at home.
Why shared decision-making matters now
The 2017 review of the Australian Prostate Cancer Registry revealed significant variation in treatment patterns across public and private hospitals. Clinicians and policy makers responded by calling for stronger consumer engagement earlier in the care pathway.
Health literacy research consistently shows that men overestimate the survival benefit of screening while underestimating the harm of overdiagnosis. Visual risk communicators, such as icon arrays showing 1,000 men, are particularly effective at conveying absolute risk intuitively.
The Therapeutic Goods Administration has also tightened the regulation of in-vitro diagnostics, raising the bar for how screening tools enter Australian practice. Developers must align their content with the latest NHMRC-approved guidelines.
Core elements of an effective decision aid
A practical decision aid typically includes a clear statement of the decision to be made, the available options, and the natural history of untreated prostate cancer. It then presents the benefits and harms of each option using plain language and absolute numbers.
High-quality examples also include values clarification exercises. These ask men to rate how they feel about potential outcomes such as incontinence, erectile dysfunction, or the anxiety of a false-positive result. The responses help clinicians tailor subsequent counselling to what matters most.
Formats vary from paper-based leaflets to interactive web tools. The AskShareKnow question prompt sheet, developed in Australia, has shown that even a simple three-question card can meaningfully change consultation behaviour.
Co-design with Australian consumers and clinicians
Co-design is now considered a non-negotiable step in developing any patient-facing resource. Brisbane-based researchers have partnered with consumer advocates from the Queensland Prostate Cancer Network to test draft materials in focus groups in Woolloongabba and the Sunshine Coast.
Clinicians from primary care, urology, radiation oncology, and nursing have contributed to iterative reviews. Their feedback has shaped the wording of risk statistics, the order of information, and follow-up prompts that align with GP software templates.
Pilot sites are experimenting with pre-consultation links through patient portals, as well as printed tear-off cards handed out at reception. Both approaches reduce time pressure on consultations and create space for genuine deliberation.
Embedding cultural safety for Aboriginal and Torres Strait Islander men
Aboriginal and Torres Strait Islander men experience disproportionately higher mortality from prostate cancer, often presenting at more advanced stages. Decision aids intended for broad Australian use must be adapted to address this disparity.
Culturally safe adaptations involve working with Aboriginal Community Controlled Health Organisations, embedding Indigenous artwork where appropriate, and ensuring language reflects community priorities. Frameworks such as the Iris Decision Aid offer a template for this work.
Embedding mental health considerations is also critical, as screening decisions often trigger anxiety. Resources on primary care mental health offer useful parallels for how screening conversations can be supported by broader psychosocial care.
From research translation to clinical practice
Even a well-designed decision aid will fail if it never reaches the clinic desk. Translation science offers a structured way to assess whether a tool is ready for routine use. Frameworks such as TDF and RE-AIM help researchers plan beyond the pilot phase.
Researchers across the Brisbane Diamantina network are encouraged to consult guidance on assessing research translation readiness before launching any new decision support resource. This structured reflection reduces pilot fatigue and supports sustainable scale-up.
Lessons from adjacent clinical areas are equally valuable. Many of the principles being applied to prostate cancer screening aids, including rapid stakeholder feedback and iterative refinement, mirror those developed in other time-sensitive clinical pathways.
Measuring impact and refining the tool
Evaluation should not stop at pilot testing. Decision aids need ongoing monitoring to ensure they remain accurate as evidence evolves, and that they continue to meet the needs of diverse patient groups. Decisional conflict scores and consultation length are useful indicators.
Data linkage with the Australian Prostate Cancer Registry offers an opportunity to track longer-term outcomes for men who used a particular aid. Such studies provide the kind of robust evidence that clinicians and policy makers need before endorsing widespread adoption. A study on treating sepsis in children showed how rapid-cycle evaluation and parent feedback loops can accelerate refinement of a time-sensitive clinical tool.
Refinement cycles should also capture clinician feedback, particularly from rural and remote practices where broadband limitations may affect digital aids. Periodic updates every two to three years keep the resource aligned with shifting guidelines.
Practical recommendations for health services and researchers
- Engage consumer representatives from the earliest design stage, including men with lived experience of prostate cancer and partners who supported them.
- Use absolute risk figures and visual formats such as icon arrays rather than percentages alone.
- Pilot the aid across urban, regional, and remote settings to capture the diversity of Australian contexts.
- Align content with current Prostate Cancer Foundation of Australia and RACGP guidance, and update when guidelines change.
- Plan for translation from the outset, including evaluation metrics and adoption pathways through Medicare-funded items.
- Embed cultural safety reviews with Aboriginal and Torres Strait Islander advisors before public release.
- Budget for ongoing maintenance, including version control and clinician training.
Health services, primary care networks, and research teams across Queensland are invited to collaborate on the next phase of decision aid development. Reach out to Brisbane Diamantina Health Partners to explore partnership opportunities, share consumer feedback, or contribute to evaluation studies that will shape how Australian men make one of the most personal decisions in modern healthcare.
